<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529645</url>
  </required_header>
  <id_info>
    <org_study_id>V113_01</org_study_id>
    <secondary_id>2011-000688-28</secondary_id>
    <nct_id>NCT01529645</nct_id>
  </id_info>
  <brief_title>Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years</brief_title>
  <official_title>Phase I, Randomized, Controlled, Observer-Blind, Dose-Ranging Study of Acellular Pertussis and Tetanus-Diptheria-Acellular Pertussis Booster Vaccine in Adults Ages 18 to 40 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of 9 different vaccines containing aP
      (acellular pertussis) and TdaP (acellular pertussis, tetanus and diphtheria) in healthy
      subjects 18 to 40 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine</measure>
    <time_frame>Day 1 through 7 after vaccination</time_frame>
    <description>The safety profiles of different antigenic formulations of the aP and TdaP booster vaccines were assessed and compared to that of licensed comparator in terms of the number of subjects reporting solicited local and systemic adverse events and other adverse events after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine</measure>
    <time_frame>From day 1 to day 365</time_frame>
    <description>The safety profiles of different antigenic formulations of the aP and TdaP booster vaccines were assessed in terms of the number of subjects reporting any unsolicited adverse events (AEs) between day 1 to day 30 , serious adverse events (SAEs) and AEs leading to premature withdrawal between day 1 to day 365, after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens Following Booster Vaccination</measure>
    <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
    <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) on aP booster groups, against pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), following vaccination with different antigenic formulations of aP versus the response to the commercially available comparator are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMCs of Antibodies in T5D2aP1, T5D2aP2 and T5D2aP4 Groups Against Pertussis Antigens Following Booster Vaccination</measure>
    <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
    <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) in TdaP Booster Groups against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of TdaP booster versus the response to the commercially available comparator are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMCs of Antibodies in T5D4aP1, T5D4aP2 and T5D4aP4 Groups Against Pertussis Antigens Following Vaccination</measure>
    <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
    <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) in TdaP booster groups, against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of TdaP booster versus the response to the commercially available comparator are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratios (GMRs) of Post Vaccination Versus Pre Vaccination GMCs of Antibodies in aP1, aP2, aP4 Booster Groups Against Pertussis Antigens</measure>
    <time_frame>Day 30 post vaccination/baseline (Day 1)</time_frame>
    <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for different antigenic formulations of aP booster vaccines and for licensed comparator are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies in T5D2aP1, T5D2aP2 and T5D2aP4 Booster Groups Against Pertussis Antigens</measure>
    <time_frame>Day 30 post vaccination/baseline (Day 1)</time_frame>
    <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for TdaP booster groups and for licensed comparator are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies for T5D4aP1, T5D4aP2 and T5D4aP4 Booster Groups Against Pertussis Antigens</measure>
    <time_frame>Day 30 post vaccination/baseline (Day 1)</time_frame>
    <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for TdaP booster groups and for licensed comparator are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With Diphtheria and Tetanus Antitoxin Units &gt;= 0.1/mL After Vaccination</measure>
    <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
    <description>The percentages of subjects demonstrating diphtheria and tetanus antitoxin units &gt;= 0.1/mL following vaccination with different antigenic formulations of TdaP booster vaccine, is compared to the response to commercially available comparator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With 2- and 4-fold Increase in GMCs Against Pertussis Antigens Following Vaccination.</measure>
    <time_frame>Day 30 post vaccination</time_frame>
    <description>Comparison of antibody responses against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of aP and TdaP booster vaccines and licensed comparator, are reported in terms of the percentages of subjects demonstrating 2- and 4-fold increase in GMCs from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMCs of Antibodies Against Diphtheria and Tetanus Antigens Following Vaccination</measure>
    <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
    <description>The GMCs of antibodies against diphtheria and tetanus antigens following vaccination with different formulations of TdaP booster are compared with the response to the commercially available comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies Against Diphtheria and Tetanus Antigens</measure>
    <time_frame>Day 30 post vaccination/Day 1</time_frame>
    <description>The GMRs of post vaccination versus pre vaccination GMCs of antibodies against diphtheria and tetanus antigens for different formulations of TdaP booster and commercially available comparator versus GMCs at baseline are reported.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Pertussis</condition>
  <condition>Whooping Cough</condition>
  <condition>Tetanus</condition>
  <condition>Lockjaw</condition>
  <condition>Diphtheria</condition>
  <arm_group>
    <arm_group_label>Group 1: aP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: aP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: aP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: TdaP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: TdaP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: TdaP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: TdaP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8: TdaP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9: TDaP booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10: Licensed TdaP booster</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Acellular pertussis vaccine</intervention_name>
    <description>Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.</description>
    <arm_group_label>Group 1: aP booster</arm_group_label>
    <arm_group_label>Group 2: aP booster</arm_group_label>
    <arm_group_label>Group 3: aP booster</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)</intervention_name>
    <description>Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.</description>
    <arm_group_label>Group 4: TdaP booster</arm_group_label>
    <arm_group_label>Group 5: TdaP booster</arm_group_label>
    <arm_group_label>Group 6: TdaP booster</arm_group_label>
    <arm_group_label>Group 7: TdaP booster</arm_group_label>
    <arm_group_label>Group 8: TdaP booster</arm_group_label>
    <arm_group_label>Group 9: TDaP booster</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed TdaP booster vaccine</intervention_name>
    <description>Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.</description>
    <arm_group_label>Group 10: Licensed TdaP booster</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)</intervention_name>
    <description>To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.</description>
    <arm_group_label>Group 1: aP booster</arm_group_label>
    <arm_group_label>Group 2: aP booster</arm_group_label>
    <arm_group_label>Group 3: aP booster</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Subjects received one injection of saline solution at one month after vaccination.</description>
    <arm_group_label>Group 4: TdaP booster</arm_group_label>
    <arm_group_label>Group 5: TdaP booster</arm_group_label>
    <arm_group_label>Group 6: TdaP booster</arm_group_label>
    <arm_group_label>Group 7: TdaP booster</arm_group_label>
    <arm_group_label>Group 8: TdaP booster</arm_group_label>
    <arm_group_label>Group 9: TDaP booster</arm_group_label>
    <arm_group_label>Group 10: Licensed TdaP booster</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female individuals between 18 and 40 years of age (inclusive) who had
             provided informed consent.

          2. Individuals who were able to be contacted for the duration of the study.

        Exclusion Criteria:

          1. Individuals who had received vaccines containing T, D, or pertussis (aP or whole
             cell), been diagnosed with pertussis disease, or who have had a household exposure to
             pertussis within the past 8 years.

          2. If female, &quot;of childbearing potential&quot;, sexually active, and had not used any of the
             &quot;acceptable contraceptive methods&quot; for at least 2 months prior to study entry:

               1. Of childbearing potential was defined as status post onset of menarche and not
                  meeting any of the following conditions: menopausal for at least 2 years, status
                  after bilateral tubal ligation for at least 1 year, status after bilateral
                  oophorectomy, or status after hysterectomy.

               2. Acceptable birth control methods were defined as one or more of the following:

                    -  Hormonal contraceptive (such as oral, injection, transdermal patch, implant,
                       cervical ring);

                    -  Barrier (condom with spermicide or diaphragm with spermicide) each and every
                       time during intercourse;

                    -  Intrauterine device (IUD);

                    -  Monogamous relationship with vasectomized partner. Partner must have been
                       vasectomized for at least six months prior to the subject's study entry.

          3. If female of childbearing potential and sexually active, refusal to use an &quot;acceptable
             contraceptive method&quot; through to 3 weeks after last study vaccination.

          4. Any positive or indeterminate pregnancy test.

          5. Female individuals who were pregnant or breastfeeding.

          6. Individuals with contraindications, warnings and/or precautions to vaccination with
             Boostrix or Td-pur as specified within the summary of product characteristics.

          7. Individuals with a clinically significant active infection (as assessed by the
             investigator) or oral body temperature ≥38°C/100.4ºF within 3 days of the intended
             date of vaccination.

          8. Known hypersensitivity or allergy to diphtheria, tetanus, or pertussis vaccine
             (including excipients of the investigational study vaccines, control or placebo as
             summarized in protocol section 5.0).

          9. Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, might have interfered with the subject's ability to
             participate in the study.

         10. Individuals with any progressive or severe neurologic disorder, seizure disorder or
             Guillian-Barré syndrome.

         11. Individuals with history or any illness that, in the opinion of the investigator,
             might have interfered with the results of the study or pose additional risk to the
             individuals due to participation in the study.

         12. Known or suspected impairment/alteration of immune function, including:

               1. Chronic use of oral steroids (≥15 days of use) within 60 days prior to visit 1
                  (day 1) (use of inhaled, intranasal, or topical corticosteroids was allowed);

               2. Receipt of parenteral steroids within 60 days prior to visit 1 (day 1);

               3. Receipt of immunostimulants within 60 days prior to visit 1 (day 1);

               4. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivates within 3 months prior to visit 1 (day 1) or planned during the full
                  length of the study;

               5. HIV infection or HIV-related disease;

               6. Heritable immunodeficiency.

         13. Abnormalities of splenic or thymic function.

         14. Individuals with a known bleeding diathesis, or any condition that might have been
             associated with a prolonged bleeding time.

         15. Individuals with any serious chronic or progressive disease according to judgment of
             the investigator (neoplasm, insulin dependent diabetes, cardiac, renal or hepatic
             disease).

         16. Individuals with body mass index (BMI) greater than or equal to 35 kg/m2 (= weight in
             kg / (height in meters x height in meters)).

         17. Individuals participating in any clinical trial with another investigational product
             30 days prior to first study visit or with intent to participate in another clinical
             study at any time during the conduct of this study.

         18. Individuals who received any other vaccines within 14 days (for inactivated vaccines)
             or 28 days (for live vaccines) prior to enrollment in this study or who were planning
             to receive any vaccine other than Td or placebo within 28 days from the study
             vaccines.

         19. Individuals who were first degree relatives of subjects involved in trial conduct.

         20. Individuals with history of substance or alcohol abuse within the past 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geert Leroux-Roels, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Vaccinology (CEVAC), Ghent University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Vaccinology (CEVAC), Ghent University Hospital</name>
      <address>
        <city>De Pintelaan</city>
        <state>B-9000 Ghent</state>
        <zip>185</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <results_first_submitted>April 30, 2014</results_first_submitted>
  <results_first_submitted_qc>September 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 18, 2014</results_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pertussis</keyword>
  <keyword>booster vaccine</keyword>
  <keyword>tetanus</keyword>
  <keyword>diphtheria in adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group aP1</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="P2">
          <title>Group aP2</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="P3">
          <title>Group aP4</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="P4">
          <title>Group T5D2aP1</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="P5">
          <title>Group T5D2aP2</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="P6">
          <title>Group T5D2aP4</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="P7">
          <title>Group T5D4aP1</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="P8">
          <title>Group T5D4aP2</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="P9">
          <title>Group T5D4aP4</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="P10">
          <title>Licensed TdaP</title>
          <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="42"/>
                <participants group_id="P8" count="42"/>
                <participants group_id="P9" count="42"/>
                <participants group_id="P10" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="41"/>
                <participants group_id="P7" count="40"/>
                <participants group_id="P8" count="42"/>
                <participants group_id="P9" count="41"/>
                <participants group_id="P10" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SAE - Premature contractions</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was done on the all enrolled set, ie, all subjects who have signed an informed consent, undergone screening procedures and were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Group aP1</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="B2">
          <title>Group aP2</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="B3">
          <title>Group aP4</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="B4">
          <title>Group T5D2aP1</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="B5">
          <title>Group T5D2aP2</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="B6">
          <title>Group T5D2aP4</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="B7">
          <title>Group T5D4aP1</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="B8">
          <title>Group T5D4aP2</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="B9">
          <title>Group T5D4aP4</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="B10">
          <title>Licensed TdaP</title>
          <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="42"/>
            <count group_id="B6" value="42"/>
            <count group_id="B7" value="42"/>
            <count group_id="B8" value="42"/>
            <count group_id="B9" value="42"/>
            <count group_id="B10" value="42"/>
            <count group_id="B11" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="5.6"/>
                    <measurement group_id="B2" value="26.8" spread="5.1"/>
                    <measurement group_id="B3" value="27.4" spread="6.5"/>
                    <measurement group_id="B4" value="26.8" spread="5.7"/>
                    <measurement group_id="B5" value="27.7" spread="5.9"/>
                    <measurement group_id="B6" value="25.8" spread="5.2"/>
                    <measurement group_id="B7" value="25.1" spread="4.2"/>
                    <measurement group_id="B8" value="27.5" spread="5.1"/>
                    <measurement group_id="B9" value="27.2" spread="5.6"/>
                    <measurement group_id="B10" value="27.4" spread="6.4"/>
                    <measurement group_id="B11" value="26.8" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="29"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="27"/>
                    <measurement group_id="B10" value="24"/>
                    <measurement group_id="B11" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="15"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine</title>
        <description>The safety profiles of different antigenic formulations of the aP and TdaP booster vaccines were assessed and compared to that of licensed comparator in terms of the number of subjects reporting solicited local and systemic adverse events and other adverse events after vaccination.</description>
        <time_frame>Day 1 through 7 after vaccination</time_frame>
        <population>Analysis was done on the safety set, ie, all subjects who received the study vaccination and provided post vaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group aP1</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group aP2</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group aP4</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Group T5D2aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O5">
            <title>Group T5D2aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O6">
            <title>Group T5D2aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O7">
            <title>Group T5D4aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O8">
            <title>Group T5D4aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O9">
            <title>Group T5D4aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O10">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine</title>
          <description>The safety profiles of different antigenic formulations of the aP and TdaP booster vaccines were assessed and compared to that of licensed comparator in terms of the number of subjects reporting solicited local and systemic adverse events and other adverse events after vaccination.</description>
          <population>Analysis was done on the safety set, ie, all subjects who received the study vaccination and provided post vaccination safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="42"/>
                <count group_id="O10" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="39"/>
                    <measurement group_id="O10" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="35"/>
                    <measurement group_id="O9" value="39"/>
                    <measurement group_id="O10" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="27"/>
                    <measurement group_id="O10" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body temperature (≥40°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic use of analgesic/antipyretic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapeutic use of analgesic/antipyretic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine</title>
        <description>The safety profiles of different antigenic formulations of the aP and TdaP booster vaccines were assessed in terms of the number of subjects reporting any unsolicited adverse events (AEs) between day 1 to day 30 , serious adverse events (SAEs) and AEs leading to premature withdrawal between day 1 to day 365, after vaccination.</description>
        <time_frame>From day 1 to day 365</time_frame>
        <population>Analysis was done on the safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group aP1</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group aP2</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group aP4</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Group T5D2aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O5">
            <title>Group T5D2aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O6">
            <title>Group T5D2aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O7">
            <title>Group T5D4aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O8">
            <title>Group T5D4aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O9">
            <title>Group T5D4aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O10">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine</title>
          <description>The safety profiles of different antigenic formulations of the aP and TdaP booster vaccines were assessed in terms of the number of subjects reporting any unsolicited adverse events (AEs) between day 1 to day 30 , serious adverse events (SAEs) and AEs leading to premature withdrawal between day 1 to day 365, after vaccination.</description>
          <population>Analysis was done on the safety set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="42"/>
                <count group_id="O10" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE (day 1 to 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="18"/>
                    <measurement group_id="O10" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (Day1 to Day 365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal (Day1 to Day 365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens Following Booster Vaccination</title>
        <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) on aP booster groups, against pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), following vaccination with different antigenic formulations of aP versus the response to the commercially available comparator are reported.</description>
        <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
        <population>Analysis was done on the per-protocol population, ie, all subjects who correctly received the vaccine, and provided evaluable serum samples at the relevant time points and had no major protocol violation as defined prior to unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Group aP1</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group aP2</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group aP4</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens Following Booster Vaccination</title>
          <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) on aP booster groups, against pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), following vaccination with different antigenic formulations of aP versus the response to the commercially available comparator are reported.</description>
          <population>Analysis was done on the per-protocol population, ie, all subjects who correctly received the vaccine, and provided evaluable serum samples at the relevant time points and had no major protocol violation as defined prior to unblinding.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" lower_limit="3.22" upper_limit="7.53"/>
                    <measurement group_id="O2" value="3.81" lower_limit="2.43" upper_limit="5.95"/>
                    <measurement group_id="O3" value="4.23" lower_limit="2.72" upper_limit="6.57"/>
                    <measurement group_id="O4" value="5.07" lower_limit="3.28" upper_limit="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (PT; N= 39,35,36,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="67" upper_limit="122"/>
                    <measurement group_id="O2" value="145" lower_limit="106" upper_limit="199"/>
                    <measurement group_id="O3" value="182" lower_limit="133" upper_limit="249"/>
                    <measurement group_id="O4" value="87" lower_limit="65" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="15" upper_limit="27"/>
                    <measurement group_id="O2" value="16" lower_limit="11" upper_limit="22"/>
                    <measurement group_id="O3" value="21" lower_limit="15" upper_limit="29"/>
                    <measurement group_id="O4" value="20" lower_limit="15" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (FHA; N= 39,35,36,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="93" upper_limit="140"/>
                    <measurement group_id="O2" value="147" lower_limit="119" upper_limit="182"/>
                    <measurement group_id="O3" value="183" lower_limit="148" upper_limit="226"/>
                    <measurement group_id="O4" value="241" lower_limit="198" upper_limit="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="14" upper_limit="28"/>
                    <measurement group_id="O2" value="16" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="O3" value="17" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O4" value="21" lower_limit="14" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (PRN; N= 39,35,36,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589" lower_limit="440" upper_limit="788"/>
                    <measurement group_id="O2" value="936" lower_limit="687" upper_limit="1273"/>
                    <measurement group_id="O3" value="1384" lower_limit="1020" upper_limit="1878"/>
                    <measurement group_id="O4" value="475" lower_limit="356" upper_limit="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMCs of Antibodies in T5D2aP1, T5D2aP2 and T5D2aP4 Groups Against Pertussis Antigens Following Booster Vaccination</title>
        <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) in TdaP Booster Groups against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of TdaP booster versus the response to the commercially available comparator are reported.</description>
        <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group T5D2aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group T5D2aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group T5D2aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>GMCs of Antibodies in T5D2aP1, T5D2aP2 and T5D2aP4 Groups Against Pertussis Antigens Following Booster Vaccination</title>
          <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) in TdaP Booster Groups against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of TdaP booster versus the response to the commercially available comparator are reported.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" lower_limit="2.86" upper_limit="6.6"/>
                    <measurement group_id="O2" value="4.97" lower_limit="3.22" upper_limit="7.67"/>
                    <measurement group_id="O3" value="4.8" lower_limit="3.15" upper_limit="7.32"/>
                    <measurement group_id="O4" value="5.07" lower_limit="3.32" upper_limit="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (PT; N= 41,38,38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="49" upper_limit="80"/>
                    <measurement group_id="O2" value="72" lower_limit="56" upper_limit="93"/>
                    <measurement group_id="O3" value="160" lower_limit="124" upper_limit="206"/>
                    <measurement group_id="O4" value="86" lower_limit="68" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="14" upper_limit="28"/>
                    <measurement group_id="O2" value="16" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="O3" value="23" lower_limit="17" upper_limit="33"/>
                    <measurement group_id="O4" value="20" lower_limit="15" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (FHA; N= 41,38,38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="69" upper_limit="100"/>
                    <measurement group_id="O2" value="90" lower_limit="74" upper_limit="109"/>
                    <measurement group_id="O3" value="118" lower_limit="97" upper_limit="143"/>
                    <measurement group_id="O4" value="241" lower_limit="200" upper_limit="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8.72" upper_limit="21"/>
                    <measurement group_id="O2" value="21" lower_limit="13" upper_limit="32"/>
                    <measurement group_id="O3" value="27" lower_limit="17" upper_limit="41"/>
                    <measurement group_id="O4" value="21" lower_limit="14" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (PRN; N= 41,38,38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445" lower_limit="317" upper_limit="626"/>
                    <measurement group_id="O2" value="803" lower_limit="567" upper_limit="1138"/>
                    <measurement group_id="O3" value="1092" lower_limit="766" upper_limit="1555"/>
                    <measurement group_id="O4" value="496" lower_limit="353" upper_limit="696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMCs of Antibodies in T5D4aP1, T5D4aP2 and T5D4aP4 Groups Against Pertussis Antigens Following Vaccination</title>
        <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) in TdaP booster groups, against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of TdaP booster versus the response to the commercially available comparator are reported.</description>
        <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group T5D4aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group T5D4aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group T5D4aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>GMCs of Antibodies in T5D4aP1, T5D4aP2 and T5D4aP4 Groups Against Pertussis Antigens Following Vaccination</title>
          <description>The GMCs of antibodies as measured by enzyme-linked immunosorbent assay (ELISA) in TdaP booster groups, against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of TdaP booster versus the response to the commercially available comparator are reported.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.74" lower_limit="5.64" upper_limit="14"/>
                    <measurement group_id="O2" value="8.2" lower_limit="5.32" upper_limit="13"/>
                    <measurement group_id="O3" value="8.06" lower_limit="5.25" upper_limit="12"/>
                    <measurement group_id="O4" value="5.07" lower_limit="3.3" upper_limit="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="64" upper_limit="108"/>
                    <measurement group_id="O2" value="93" lower_limit="72" upper_limit="120"/>
                    <measurement group_id="O3" value="157" lower_limit="122" upper_limit="202"/>
                    <measurement group_id="O4" value="93" lower_limit="72" upper_limit="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="17" upper_limit="33"/>
                    <measurement group_id="O2" value="27" lower_limit="20" upper_limit="38"/>
                    <measurement group_id="O3" value="26" lower_limit="18" upper_limit="36"/>
                    <measurement group_id="O4" value="20" lower_limit="15" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="96" upper_limit="140"/>
                    <measurement group_id="O2" value="100" lower_limit="83" upper_limit="121"/>
                    <measurement group_id="O3" value="113" lower_limit="94" upper_limit="135"/>
                    <measurement group_id="O4" value="252" lower_limit="210" upper_limit="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="20" upper_limit="47"/>
                    <measurement group_id="O2" value="22" lower_limit="14" upper_limit="34"/>
                    <measurement group_id="O3" value="28" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="O4" value="21" lower_limit="14" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="837" lower_limit="624" upper_limit="1124"/>
                    <measurement group_id="O2" value="680" lower_limit="510" upper_limit="906"/>
                    <measurement group_id="O3" value="1024" lower_limit="772" upper_limit="1359"/>
                    <measurement group_id="O4" value="506" lower_limit="381" upper_limit="671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With 2- and 4-fold Increase in GMCs Against Pertussis Antigens Following Vaccination.</title>
        <description>Comparison of antibody responses against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of aP and TdaP booster vaccines and licensed comparator, are reported in terms of the percentages of subjects demonstrating 2- and 4-fold increase in GMCs from baseline.</description>
        <time_frame>Day 30 post vaccination</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group aP1</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group aP2</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group aP4</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Group T5D2aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O5">
            <title>Group T5D2aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O6">
            <title>Group T5D2aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O7">
            <title>Group T5D4aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O8">
            <title>Group T5D4aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O9">
            <title>Group T5D4aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O10">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With 2- and 4-fold Increase in GMCs Against Pertussis Antigens Following Vaccination.</title>
          <description>Comparison of antibody responses against pertussis antigens (PT, FHA and PRN), following vaccination with different antigenic formulations of aP and TdaP booster vaccines and licensed comparator, are reported in terms of the percentages of subjects demonstrating 2- and 4-fold increase in GMCs from baseline.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="39"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-Fold (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O3" value="94" lower_limit="81" upper_limit="99"/>
                    <measurement group_id="O4" value="95" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O5" value="95" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O6" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O7" value="89" lower_limit="75" upper_limit="97"/>
                    <measurement group_id="O8" value="90" lower_limit="76" upper_limit="97"/>
                    <measurement group_id="O9" value="95" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O10" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Fold (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O2" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O3" value="92" lower_limit="78" upper_limit="98"/>
                    <measurement group_id="O4" value="80" lower_limit="65" upper_limit="91"/>
                    <measurement group_id="O5" value="76" lower_limit="60" upper_limit="89"/>
                    <measurement group_id="O6" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O7" value="81" lower_limit="65" upper_limit="92"/>
                    <measurement group_id="O8" value="77" lower_limit="61" upper_limit="89"/>
                    <measurement group_id="O9" value="93" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O10" value="98" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Fold (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="69" upper_limit="94"/>
                    <measurement group_id="O2" value="94" lower_limit="81" upper_limit="99"/>
                    <measurement group_id="O3" value="89" lower_limit="74" upper_limit="97"/>
                    <measurement group_id="O4" value="80" lower_limit="65" upper_limit="91"/>
                    <measurement group_id="O5" value="95" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O6" value="95" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O7" value="76" lower_limit="59" upper_limit="88"/>
                    <measurement group_id="O8" value="77" lower_limit="61" upper_limit="89"/>
                    <measurement group_id="O9" value="90" lower_limit="76" upper_limit="97"/>
                    <measurement group_id="O10" value="95" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Fold (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="42" upper_limit="74"/>
                    <measurement group_id="O2" value="83" lower_limit="66" upper_limit="93"/>
                    <measurement group_id="O3" value="83" lower_limit="67" upper_limit="94"/>
                    <measurement group_id="O4" value="46" lower_limit="31" upper_limit="63"/>
                    <measurement group_id="O5" value="61" lower_limit="43" upper_limit="76"/>
                    <measurement group_id="O6" value="58" lower_limit="41" upper_limit="74"/>
                    <measurement group_id="O7" value="46" lower_limit="29" upper_limit="63"/>
                    <measurement group_id="O8" value="56" lower_limit="40" upper_limit="72"/>
                    <measurement group_id="O9" value="53" lower_limit="36" upper_limit="68"/>
                    <measurement group_id="O10" value="83" lower_limit="67" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Fold (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O4" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O7" value="97" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O8" value="92" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O9" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O10" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Fold (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O2" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O4" value="90" lower_limit="77" upper_limit="97"/>
                    <measurement group_id="O5" value="95" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O6" value="97" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O7" value="89" lower_limit="75" upper_limit="97"/>
                    <measurement group_id="O8" value="85" lower_limit="69" upper_limit="94"/>
                    <measurement group_id="O9" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O10" value="90" lower_limit="76" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMCs of Antibodies Against Diphtheria and Tetanus Antigens Following Vaccination</title>
        <description>The GMCs of antibodies against diphtheria and tetanus antigens following vaccination with different formulations of TdaP booster are compared with the response to the commercially available comparator.</description>
        <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group aP1</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group aP2</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group aP4</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Group T5D2aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O5">
            <title>Group T5D2aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O6">
            <title>Group T5D2aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O7">
            <title>Group T5D4aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O8">
            <title>Group T5D4aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O9">
            <title>Group T5D4aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O10">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>GMCs of Antibodies Against Diphtheria and Tetanus Antigens Following Vaccination</title>
          <description>The GMCs of antibodies against diphtheria and tetanus antigens following vaccination with different formulations of TdaP booster are compared with the response to the commercially available comparator.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="39"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (diphteria; N=42,38,39,41,38,40,37,39,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.27" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.43" lower_limit="0.28" upper_limit="0.65"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.17" upper_limit="0.38"/>
                    <measurement group_id="O4" value="0.31" lower_limit="0.2" upper_limit="0.46"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.098" upper_limit="0.23"/>
                    <measurement group_id="O6" value="0.29" lower_limit="0.19" upper_limit="0.44"/>
                    <measurement group_id="O7" value="0.31" lower_limit="0.2" upper_limit="0.48"/>
                    <measurement group_id="O8" value="0.25" lower_limit="0.16" upper_limit="0.39"/>
                    <measurement group_id="O9" value="0.25" lower_limit="0.17" upper_limit="0.39"/>
                    <measurement group_id="O10" value="0.3" lower_limit="0.19" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (diphteria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.32" upper_limit="0.49"/>
                    <measurement group_id="O2" value="0.39" lower_limit="0.31" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.37" lower_limit="0.29" upper_limit="0.46"/>
                    <measurement group_id="O4" value="1.48" lower_limit="1.1" upper_limit="1.99"/>
                    <measurement group_id="O5" value="1.41" lower_limit="1.04" upper_limit="1.92"/>
                    <measurement group_id="O6" value="1.63" lower_limit="1.2" upper_limit="2.21"/>
                    <measurement group_id="O7" value="2.7" lower_limit="1.97" upper_limit="3.69"/>
                    <measurement group_id="O8" value="2.19" lower_limit="1.62" upper_limit="2.97"/>
                    <measurement group_id="O9" value="2.47" lower_limit="1.83" upper_limit="3.33"/>
                    <measurement group_id="O10" value="1.79" lower_limit="1.32" upper_limit="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (tetanus; N=42,38,39,41,38,40,37,39,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" lower_limit="1.9" upper_limit="3.16"/>
                    <measurement group_id="O2" value="2.11" lower_limit="1.61" upper_limit="2.76"/>
                    <measurement group_id="O3" value="2.27" lower_limit="1.74" upper_limit="2.96"/>
                    <measurement group_id="O4" value="1.93" lower_limit="1.44" upper_limit="2.58"/>
                    <measurement group_id="O5" value="1.99" lower_limit="1.47" upper_limit="2.68"/>
                    <measurement group_id="O6" value="2.07" lower_limit="1.54" upper_limit="2.77"/>
                    <measurement group_id="O7" value="2.04" lower_limit="1.5" upper_limit="2.76"/>
                    <measurement group_id="O8" value="2.62" lower_limit="1.95" upper_limit="3.53"/>
                    <measurement group_id="O9" value="1.92" lower_limit="1.43" upper_limit="2.58"/>
                    <measurement group_id="O10" value="1.89" lower_limit="1.41" upper_limit="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (tetanus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.91" upper_limit="2.52"/>
                    <measurement group_id="O2" value="2.18" lower_limit="1.88" upper_limit="2.52"/>
                    <measurement group_id="O3" value="2.19" lower_limit="1.89" upper_limit="2.53"/>
                    <measurement group_id="O4" value="8.15" lower_limit="6.73" upper_limit="9.88"/>
                    <measurement group_id="O5" value="8.82" lower_limit="7.23" upper_limit="11"/>
                    <measurement group_id="O6" value="7.01" lower_limit="5.74" upper_limit="8.56"/>
                    <measurement group_id="O7" value="8.23" lower_limit="6.73" upper_limit="10"/>
                    <measurement group_id="O8" value="6.82" lower_limit="5.6" upper_limit="8.32"/>
                    <measurement group_id="O9" value="7.44" lower_limit="6.13" upper_limit="9.04"/>
                    <measurement group_id="O10" value="8.49" lower_limit="6.99" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies Against Diphtheria and Tetanus Antigens</title>
        <description>The GMRs of post vaccination versus pre vaccination GMCs of antibodies against diphtheria and tetanus antigens for different formulations of TdaP booster and commercially available comparator versus GMCs at baseline are reported.</description>
        <time_frame>Day 30 post vaccination/Day 1</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group aP1</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group aP2</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group aP4</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Group T5D2aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O5">
            <title>Group T5D2aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O6">
            <title>Group T5D2aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O7">
            <title>Group T5D4aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O8">
            <title>Group T5D4aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O9">
            <title>Group T5D4aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O10">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies Against Diphtheria and Tetanus Antigens</title>
          <description>The GMRs of post vaccination versus pre vaccination GMCs of antibodies against diphtheria and tetanus antigens for different formulations of TdaP booster and commercially available comparator versus GMCs at baseline are reported.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="39"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30/day 1 (diphtheria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.94" upper_limit="1.16"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.93" upper_limit="1.17"/>
                    <measurement group_id="O3" value="1.19" lower_limit="1.07" upper_limit="1.33"/>
                    <measurement group_id="O4" value="5.24" lower_limit="3.66" upper_limit="7.49"/>
                    <measurement group_id="O5" value="8.58" lower_limit="5.91" upper_limit="12"/>
                    <measurement group_id="O6" value="5.62" lower_limit="3.87" upper_limit="8.16"/>
                    <measurement group_id="O7" value="9.18" lower_limit="6.3" upper_limit="13"/>
                    <measurement group_id="O8" value="8.39" lower_limit="5.81" upper_limit="12"/>
                    <measurement group_id="O9" value="9.54" lower_limit="6.64" upper_limit="14"/>
                    <measurement group_id="O10" value="6.1" lower_limit="4.25" upper_limit="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30/day 1 (tetanus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.88" upper_limit="1.02"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.86" upper_limit="1"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.9" upper_limit="1.04"/>
                    <measurement group_id="O4" value="4.2" lower_limit="3.01" upper_limit="5.86"/>
                    <measurement group_id="O5" value="4.43" lower_limit="3.14" upper_limit="6.26"/>
                    <measurement group_id="O6" value="3.43" lower_limit="2.43" upper_limit="4.84"/>
                    <measurement group_id="O7" value="4.02" lower_limit="2.83" upper_limit="5.71"/>
                    <measurement group_id="O8" value="2.64" lower_limit="1.88" upper_limit="3.71"/>
                    <measurement group_id="O9" value="3.86" lower_limit="2.76" upper_limit="5.41"/>
                    <measurement group_id="O10" value="4.5" lower_limit="3.21" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratios (GMRs) of Post Vaccination Versus Pre Vaccination GMCs of Antibodies in aP1, aP2, aP4 Booster Groups Against Pertussis Antigens</title>
        <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for different antigenic formulations of aP booster vaccines and for licensed comparator are reported.</description>
        <time_frame>Day 30 post vaccination/baseline (Day 1)</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group aP1</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group aP2</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group aP4</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios (GMRs) of Post Vaccination Versus Pre Vaccination GMCs of Antibodies in aP1, aP2, aP4 Booster Groups Against Pertussis Antigens</title>
          <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for different antigenic formulations of aP booster vaccines and for licensed comparator are reported.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30/Day 1 (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="12" upper_limit="26"/>
                    <measurement group_id="O2" value="36" lower_limit="24" upper_limit="54"/>
                    <measurement group_id="O3" value="49" lower_limit="33" upper_limit="73"/>
                    <measurement group_id="O4" value="17" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30/Day 1 (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" lower_limit="3.99" upper_limit="7.54"/>
                    <measurement group_id="O2" value="9.42" lower_limit="6.74" upper_limit="13"/>
                    <measurement group_id="O3" value="9.39" lower_limit="6.75" upper_limit="13"/>
                    <measurement group_id="O4" value="12" lower_limit="8.73" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30/Day 1 (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="21" upper_limit="44"/>
                    <measurement group_id="O2" value="58" lower_limit="39" upper_limit="86"/>
                    <measurement group_id="O3" value="81" lower_limit="54" upper_limit="119"/>
                    <measurement group_id="O4" value="24" lower_limit="16" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies in T5D2aP1, T5D2aP2 and T5D2aP4 Booster Groups Against Pertussis Antigens</title>
        <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for TdaP booster groups and for licensed comparator are reported.</description>
        <time_frame>Day 30 post vaccination/baseline (Day 1)</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group T5D2aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group T5D2aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group T5D2aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies in T5D2aP1, T5D2aP2 and T5D2aP4 Booster Groups Against Pertussis Antigens</title>
          <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for TdaP booster groups and for licensed comparator are reported.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30/Day 1 (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="9.58" upper_limit="21"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="O3" value="31" lower_limit="21" upper_limit="46"/>
                    <measurement group_id="O4" value="17" lower_limit="12" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30/Day 1 (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="3.21" upper_limit="5.6"/>
                    <measurement group_id="O2" value="5.02" lower_limit="3.76" upper_limit="6.71"/>
                    <measurement group_id="O3" value="5.11" lower_limit="3.83" upper_limit="6.83"/>
                    <measurement group_id="O4" value="12" lower_limit="9.01" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30/Day 1 (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="O2" value="38" lower_limit="25" upper_limit="57"/>
                    <measurement group_id="O3" value="46" lower_limit="31" upper_limit="69"/>
                    <measurement group_id="O4" value="24" lower_limit="16" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies for T5D4aP1, T5D4aP2 and T5D4aP4 Booster Groups Against Pertussis Antigens</title>
        <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for TdaP booster groups and for licensed comparator are reported.</description>
        <time_frame>Day 30 post vaccination/baseline (Day 1)</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group T5D4aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group T5D4aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group T5D4aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>GMRs of Post Vaccination Versus Pre Vaccination GMCs of Antibodies for T5D4aP1, T5D4aP2 and T5D4aP4 Booster Groups Against Pertussis Antigens</title>
          <description>The GMRs of post-vaccination versus pre-vaccination GMCs of antibodies against pertussis antigens (PT, FHA and PRN) for TdaP booster groups and for licensed comparator are reported.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30/Day 1 (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" lower_limit="6.38" upper_limit="14"/>
                    <measurement group_id="O2" value="12" lower_limit="7.9" upper_limit="17"/>
                    <measurement group_id="O3" value="20" lower_limit="14" upper_limit="29"/>
                    <measurement group_id="O4" value="17" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30/Day 1 (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.47" upper_limit="6.38"/>
                    <measurement group_id="O2" value="3.95" lower_limit="2.94" upper_limit="5.31"/>
                    <measurement group_id="O3" value="4.39" lower_limit="3.28" upper_limit="5.89"/>
                    <measurement group_id="O4" value="12" lower_limit="8.91" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30/Day 1 (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="18" upper_limit="42"/>
                    <measurement group_id="O2" value="32" lower_limit="21" upper_limit="48"/>
                    <measurement group_id="O3" value="36" lower_limit="24" upper_limit="54"/>
                    <measurement group_id="O4" value="24" lower_limit="16" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Diphtheria and Tetanus Antitoxin Units &gt;= 0.1/mL After Vaccination</title>
        <description>The percentages of subjects demonstrating diphtheria and tetanus antitoxin units &gt;= 0.1/mL following vaccination with different antigenic formulations of TdaP booster vaccine, is compared to the response to commercially available comparator.</description>
        <time_frame>Day 1 (baseline) and Day 30 post vaccination</time_frame>
        <population>Analysis was done on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group aP1</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group aP2</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O3">
            <title>Group aP4</title>
            <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
          </group>
          <group group_id="O4">
            <title>Group T5D2aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O5">
            <title>Group T5D2aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O6">
            <title>Group T5D2aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O7">
            <title>Group T5D4aP1</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O8">
            <title>Group T5D4aP2</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O9">
            <title>Group T5D4aP4</title>
            <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
          </group>
          <group group_id="O10">
            <title>Licensed TdaP</title>
            <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Diphtheria and Tetanus Antitoxin Units &gt;= 0.1/mL After Vaccination</title>
          <description>The percentages of subjects demonstrating diphtheria and tetanus antitoxin units &gt;= 0.1/mL following vaccination with different antigenic formulations of TdaP booster vaccine, is compared to the response to commercially available comparator.</description>
          <population>Analysis was done on the per-protocol population.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="39"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (diphteria; N=42,38,39,41,38,40,37,39,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="63" upper_limit="90"/>
                    <measurement group_id="O2" value="89" lower_limit="75" upper_limit="97"/>
                    <measurement group_id="O3" value="72" lower_limit="55" upper_limit="85"/>
                    <measurement group_id="O4" value="71" lower_limit="54" upper_limit="84"/>
                    <measurement group_id="O5" value="68" lower_limit="51" upper_limit="82"/>
                    <measurement group_id="O6" value="85" lower_limit="70" upper_limit="94"/>
                    <measurement group_id="O7" value="81" lower_limit="65" upper_limit="92"/>
                    <measurement group_id="O8" value="72" lower_limit="55" upper_limit="85"/>
                    <measurement group_id="O9" value="78" lower_limit="62" upper_limit="89"/>
                    <measurement group_id="O10" value="80" lower_limit="64" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (diphteria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="73" upper_limit="96"/>
                    <measurement group_id="O2" value="97" lower_limit="85" upper_limit="100"/>
                    <measurement group_id="O3" value="81" lower_limit="64" upper_limit="92"/>
                    <measurement group_id="O4" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O5" value="97" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O6" value="95" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O7" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O9" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O10" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (tetanus; N=42,38,39,41,38,40,37,39,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O6" value="95" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O7" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O9" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O10" value="95" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (tetanus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O6" value="97" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O9" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O10" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited and unsolicited AEs collected from Day 1 to Day 7; SAEs, medically attended AEs and AEs leading to withdrawal collected from Day 1 to Day 365.</time_frame>
      <desc>Analysis was done on the safety population; two subjects, in groups aP4 and T5D4aP1were excluded for not providing any postbaseline safety data. Solicited AEs are categorized as systematic and unsolicited AEs are categorized as non-systematic.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group aP1</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a low dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="E2">
          <title>Group aP2</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a medium dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="E3">
          <title>Group aP4</title>
          <description>Subjects received a single dose of aP booster vaccine (containing a high dose of PT, FHA and PRN antigens) on day 1 of this study.</description>
        </group>
        <group group_id="E4">
          <title>Group T5D2aP1</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="E5">
          <title>Group T5D2aP2</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="E6">
          <title>Group T5D2aP4</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a low dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="E7">
          <title>Group T5D4aP1</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a low dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="E8">
          <title>Group T5D4aP2</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a medium dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="E9">
          <title>Group T5D4aP4</title>
          <description>Subjects received a single dose of TdaP booster vaccine (containing a high dose of PT, FHA, PRN antigens, a double dose of diphtheria toxoid and a fixed dose of tetanus toxoid) on day 1 of this study.</description>
        </group>
        <group group_id="E10">
          <title>Licensed TdaP</title>
          <description>Subjects received a single dose of a comparator TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) on day 1 of this study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="40" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="39" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="40" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="36" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site movement impairment</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="40" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="39" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="31" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

